Back to Top Skip to main content the official website of the Military Health System (MHS) and the Defense Health Agency (DHA)

Utility Navigation Links

Alert Arrow ALERT!!

NEW FEATURE AVAILABLE – CHECK IT OUT: There is a new SHOW MARKUP button that allows you to view the manuals in a whole new way. Show or hide revisions in a section; the choice is yours. Go to any page within the manuals and use the new button now!

The Managed Care Support (MCS) Manuals (T-3) for contracts prior to 07/21/2016 are now superseded and can be found in the "Superseded" portion (indicated by a red banner) of each T-17 manuals' web page.

TRICARE Policy Manual 6010.60-M, April 1, 2015
Chapter 7
Section 15.1
Neurology And Neuromuscular Services
Issue Date:  April 19, 1983
Copyright:  CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.
Revision:  C-95, January 20, 2022
20552, 20553, 95812 - 95999
2.0  HCPCS Procedure Code
The diagnosis and treatment of muscle and nerve disorders.
4.1  Neurology and neuromuscular services are covered.
4.2  The Epley Canalith Repositioning Procedure (CRP) is covered for the treatment of Benign Paroxysmal Positional Vertigo (BPPV) with an effective date of June 13, 2012.
4.3  Off-label use of rituximab may be considered for cost-sharing for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The effective date is July 16, 2010.
4.4  Off-label use of rituximab injections may be considered for cost-sharing for the treatment of Stiff Person Syndrome. The effective date is March 31, 2005.
4.5  Off-label use of rituximab injections may be considered for cost-sharing for the treatment of Multiple Sclerosis (MS). The effective date is February 14, 2008.
5.0  Exclusions
5.1  Topographic brain mapping (HCPCS S8040) is unproven.
5.2  Microcurrent Electrical Therapy (MET), Cranial Electrotherapy Stimulation (CES), or any therapy that uses the non-invasive application of low levels of microcurrent stimulation to the head by means of external electrodes for the treatment of anxiety, depression, insomnia, Post-Traumatic Stress Disorder (PTSD), pain, or migraines and electrical stimulation devices used to apply this therapy, are unproven.
5.3  Magnetic Resonance Guided High-Intensity Focused Ultrasound Surgery (MRgFUS) (CPT 0398T) for the treatment of essential tremor is unproven.
5.4  External trigeminal nerve stimulation (eTNS), also referred to as transcutaneous supraorbital neurostimulation (t-SNS), for the prevention and/or treatment of migraines is unproven.
5.5  Monoclonal antibodies (such as aducanumab) for the prevention, treatment, or mitigation of symptoms related to Mild Cognitive Impairment (MCI) or Alzheimer’s disease (AD) is unproven.
- END -

Utility Navigation Links

DoD Seal is the official website of the Defense Health Agency (DHA) a component of the Military Health System

TRICARE is a registered trademark of the Department of Defense (DoD), DHA. All rights reserved.

CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

If you have a question regarding TRICARE benefits, please go to the TRICARE Contact Us page page.
If you need help with technical/operational issues, please go to the TRICARE Manuals Online Help page.

The appearance of hyperlinks to external websites does not constitute endorsement by the DHA of these websites or the information, products or services contained therein. For other than authorized government activities, the DHA does not exercise any editorial control over the information you may find at other locations. Such links are provided consistent with the stated purpose of this DoD website.


DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.